Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial
| Autor: | K. de Mari, Hyone-Myong Eun, Laurence Maynard, Bernard Lebreux |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Parvovirus Canine medicine.medical_treatment Placebo Gastroenterology Body Temperature Enteritis Parvoviridae Infections Dogs Internal medicine medicine Animals Dog Diseases Survival rate General Veterinary biology Parvovirus business.industry Canine parvovirus Viral Vaccines General Medicine Immunotherapy biology.organism_classification medicine.disease Survival Rate Clinical trial Treatment Outcome Interferon Type I Cohort Immunology Female business |
| Zdroj: | Veterinary Record. 152:105-108 |
| ISSN: | 0042-4900 |
| Popis: | The clinical efficacy of a recombinant feline interferon (IFN) (type omega) was evaluated under field conditions for the treatment of dogs with parvoviral enteritis. In this multicentric, double-blind, placebo-controlled trial, 94 dogs from one to 28 months old were randomly assigned to two groups which were treated intravenously either with IFN (2.5 million units/kg) or placebo once a day for three consecutive days, and monitored for clinical signs and mortality for 10 days. Each dog received individual supportive treatment The data from 92 interpretable cases (43 IFN-treated and 49 placebo) showed that the clinical signs of the IFN-treated animals improved significantly in comparison with the control animals, and that there were only three deaths in the IFN group compared with 14 deaths in the placebo group (P = 0.0096) corresponding to a 4.4-fold reduction. Alternative analyses of the data taking into account the prior vaccination status of the dogs against canine parvovirus suggested that the IFN therapy resulted in a 6.4-fold reduction in mortality (P = 0.044) in the unvaccinated cohort, a significant reduction when compared with the vaccinated cohort. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text